ArticleOncogene2000
Cooperation between AP1 and PEA3 sites within the progression elevated gene-3 (PEG-3) promoter regulate basal and differential expression of PEG-3 during progression of the oncogenic phenotype in transformed rat embryo cells.
Article in Oncogene, 2000. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 44 citations in OpenAlex.
- Article
- MRI detection of the malignant transformation of stem cells through reporter gene expression driven by a tumor-specific promoter.Stem cell research & therapy · 2021Article
- Article
- Enhanced prostate cancer gene transfer and therapy using a novel serotype chimera cancer terminator virus (Ad.5/3-CTV).Journal of cellular physiology · 2014Article
- Selected approaches for rational drug design and high throughput screening to identify anti-cancer molecules.Anti-cancer agents in medicinal chemistry · 2012Review
- Chapter One---Cancer terminator viruses and approaches for enhancing therapeutic outcomes.Advances in cancer research · 2012Review
- The role of Pea3 group transcription factors in esophageal squamous cell carcinoma.The American journal of pathology · 2011Article
- IL-6 promotes prostate tumorigenesis and progression through autocrine cross-activation of IGF-IR.Oncogene · 2011Article
- Tumor-specific imaging through progression elevated gene-3 promoter-driven gene expression.Nature medicine · 2011Article
- Developing an effective gene therapy for prostate cancer: New technologies with potential to translate from the laboratory into the clinic.Discovery medicine · 2011Review
- Discoidin domain receptor 2 is associated with the increased expression of matrix metalloproteinase-13 in synovial fibroblasts of rheumatoid arthritis.Molecular and cellular biochemistry · 2009Article
- A cancer terminator virus eradicates both primary and distant human melanomas.Cancer gene therapy · 2008Article
- mda-7/IL-24: multifunctional cancer-specific apoptosis-inducing cytokine.Pharmacology & therapeutics · 2006Review
- Ionizing radiation enhances adenoviral vector expressing mda-7/IL-24-mediated apoptosis in human ovarian cancer.Journal of cellular physiology · 2006Article
- Dual cancer-specific targeting strategy cures primary and distant breast carcinomas in nude mice.Proceedings of the National Academy of Sciences of the United States of America · 2005Article
- Targeting gene expression selectively in cancer cells by using the progression-elevated gene-3 promoter.Proceedings of the National Academy of Sciences of the United States of America · 2005Article
- p62 overexpression in breast tumors and regulation by prostate-derived Ets factor in breast cancer cells.Oncogene · 2003Article
- Insights into glutamate transport regulation in human astrocytes: cloning of the promoter for excitatory amino acid transporter 2 (EAAT2).Proceedings of the National Academy of Sciences of the United States of America · 2003Article
- Article
- PEA3 sites within the progression elevated gene-3 (PEG-3) promoter and mitogen-activated protein kinase contribute to differential PEG-3 expression in Ha-ras and v-raf oncogene transformed rat embryo cells.Nucleic acids research · 2001Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
Abstract
Cancer is a progressive disease in which a tumor cell temporally develops qualitatively new transformation related phenotypes or a further elaboration of existing transformation associated properties. Subtraction hybridization identified a novel gene associated with transformation progression in mutant adenovirus type 5, H5ts125, transformed rat embryo cells, progression elevated gene-3 (PEG-3). To define the mechanism by which expression of PEG-3 is enhanced as a function of cancer progression a 5'-flanking promoter region of approximately 2.0-kb, PEG-Prom, was isolated, cloned and characterized. The full-length and various mutated regions of the PEG-Prom were linked to a luciferase reporter construct and evaluated for promoter activity during cancer progression. These assays demonstrate a requirement for AP1 and PEA3 sites adjacent to the TATA box region of PEG-3 in mediating basal promoter activity and the enhanced expression of PEG-3 in progressed H5ts125-transformed rat embryo cells. An involvement of AP1 and PEA3 in PEG-3 regulation was also confirmed by electrophoretic mobility shift assays (EMSA) and transfection studies with cJun and PEA3 expression vectors. Our findings document the importance of both AP1 and PEA3 transcription factors in mediating basal and elevated expression of PEG-3 in H5ts125-transformed rat embryo cells displaying an aggressive and progressed cancer phenotype.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.